---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006330"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:06:35.839123+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics reduces warrant exercise prices to $1.75; enters voting agreements ahead of special meeting

## Summary
- Company repriced ~913,638 warrants held by certain holders from $8.30-$47.60 down to $1.75.
- Board unilaterally reduced exercise prices of remaining ~762,787 warrants to $1.75.
- Holders agreed to vote shares in favor of proposals at Feb 26, 2026 special meeting.
- New exercise price of $1.75 equals Nasdaq Minimum Price per applicable rules.

## SEC filing metadata
- accession: 0001493152-26-006330
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315226006330/0001493152-26-006330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315226006330/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006330
- JSON: https://secwatch.observer/filing/0001493152-26-006330.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006330.txt

## Key facts
- Material Agreements
  Indaptus Therapeutics, Inc. entered into Repricing Agreements with Executing Holders (effective 2026-02-11).
  - Action: entry
  - Counterparty: Executing Holders
  - Effective: 2026-02-11
  source text: On February 11, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into warrant repricing agreements (the “Repricing Agreements”) with certain holders (the “Executing Holders”) of warrants to purchase an aggregate of 913,638 shares of common stock of the Company that were originally issued in financing rounds during 2024 and 2025 at exercise prices ranging from $8.30 to $47.60 (the “Executing Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315226006330/0001493152-26-006330-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.